OncoMed Pharmaceuticals Inc (OMED.OQ)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2018||Chairman of the Board|
|45||2017||Chief Financial Officer, Executive Vice President, Corporate Development and Finance and President|
|64||2018||President, Executive Vice President - Research and Development|
|51||Senior Vice President, Molecular and Cellular Biology|
|56||Senior Vice President, Cancer Biology|
- BRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has Resigned
- BRIEF-OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln
- BRIEF-Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals
- BRIEF-Oncomed says CEO Paul Hastings to Resume Chairman of Board Responsibilities
- BRIEF-Oncomed posts Q3 loss per share $0.28